Hemlibra is a once-weekly injection for patients with hemophilia A who have developed a resistance to other treatments.
The drug’s label contains a black box warning over the risk of severe blood clots in patients who receive a rescue treatment for breakthrough bleeds while taking Hemlibra.
“Today’s approval of Hemlibra represents an important advancement for people with hemophilia A with inhibitors, who have struggled to manage their bleeding disorder and haven’t had a new medicine in nearly 20 years,” said Sandra Horning, MD, chief medical officer and head of global product development for Genentech.
More articles on supply chain:
Prime Healthcare taps HealthTrust for GPO services
Acorda Therapeutics halts Parkinson’s drug trials after 5 patient deaths
Cardinal Health to sell Chinese distribution business to Shanghai Pharma
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.